ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the reti...

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the reti...

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. This study is a double-masked, sham-controlled, parallel design prospective, mul...

AMD affects 15 million Americans, with 200,000 new advanced cases diagnosed each year. AMD is the leading cause of blindness in this country, from either the “dry” or “wet” advanced forms. At present, there is no treatment for dry AMD. Besides bl...

The purpose of this study is to learn more about age-related macular degeneration (AMD) by using a new investigational technology, AO-(adaptive optics) OCT (optical coherence tomography) with hyperspectral autofluorescence (AF). While currently there is no cure for AMD,...

Age-related macular degeneration (AMD) is the leading cause of blindness in our country, and heart attack and stroke are leading causes of death. We have discovered that AMD and these lethal systemic diseases may be linked by a special form of AMD called “reticula...